Literature DB >> 660556

Regional and subcellular distribution and some factors in the regulation of reduced pterins in rat brain.

W P Bullard, P B Guthrie, P V Russo, A J Mandell.   

Abstract

We have studied the regional and subcellular distribution, functional role, and pharmacology of quinoid dihydropterin reductase (QDPR) and endogenous reduced pterins (PH4) subserving tyrosin hydroxylase (TOH) and tryptophan hydroxylase in the rat brain. There is a significant correlation between the regional distribution of PH4 and TOH but not between PH4 and tryptophan hydroxylase or between either TOH or tryptophan hydroxylase and QDPR. This suggests that a major portion of PH4 is associated with the biosynthetic activity of brain catecholaminergic systems. The regional and subcellular distribution of QDPR was inconsistent with a regulatory function for QDPR in monoamine synthesis. In vitro measures of PH4, TOH, and synaptosomal dopamine (DA) and serotonin synthesis in the striate cortex of untreated animals and animals subjected to neurotoxin or electrolytic lesions of the dorsal raphe or substantia nigra exhibit significant covariation of PH4 with synaptosomal DA but not serotonin synthesis and a significant partial correlation of PH4 with DA synthesis. The subcellular distribution of PH4 in the striatum demonstrates an association of PH4 with the biosynthetic function of dopaminergic nerve terminals. Reserpine and d-amphetamine in vivo elicited an increase and decrease, respectively, in striatal PH4 paralleling induced changes in synaptosomal DA synthesis. Other drugs altering central catecholaminergic function did not alter striatal PH4 levels significantly. The data suggest that 1) a major portion of total PH4 (as much as 90% in the striatum) is related to the function of catecholaminergic rather than serotonergic systems, 2) PH4 levels is a determinant of the velocity of DA synthesis and 3) PH4 levels are altered by some psychoactive drugs in association with changes in synaptosomal catecholamine biosynthetic rates.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 660556

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Scattering kinetics in a complex tryptophan hydroxylase preparation from rat brainstem raphe nuclei: statistical evidence that the lithium-induced sigmoid velocity function reflects two states of available catalytic potential.

Authors:  S Knapp; A J Mandell
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

2.  Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey.

Authors:  Y Tani; T Ishihara; T Kanai; T Ohno; J Andersson; A Lilja; G Antoni; K J Fasth; P Bjurling; G Westerberg
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Tetrahydrobiopterin increases in adrenal medulla and cortex: a factor in the regulation of tyrosine hydroxylase.

Authors:  M M Abou-Donia; O H Viveros
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

4.  Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphine.

Authors:  G Laschinski; B Kittner; M Bräutigam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

5.  CFS hydroxylase cofactor levels in some neurological diseases.

Authors:  A C Williams; R A Levine; T N Chase; W Lovenberg; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-08       Impact factor: 10.154

6.  Conformational influences on brain tryptophan hydroxylase by submicromolar calcium: opposite effects of equimolar lithium.

Authors:  S Knapp; A J Mandell
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

7.  Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives.

Authors:  G Laschinski; B Kittner; M Bräutigam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.